Cargando…
The clinical and molecular diversity of mast cell leukemia with or without associated hematologic neoplasm
Mast cell leukemia is a rare variant of advanced systemic mastocytosis characterized by at least 20% of mast cells in a bone marrow smear. We evaluated clinical and molecular characteristics of 28 patients with (n=20, 71%) or without an associated hematologic neoplasm. De novo mast cell leukemia was...
Autores principales: | Jawhar, Mohamad, Schwaab, Juliana, Meggendorfer, Manja, Naumann, Nicole, Horny, Hans-Peter, Sotlar, Karl, Haferlach, Torsten, Schmitt, Karla, Fabarius, Alice, Valent, Peter, Hofmann, Wolf-Karsten, Cross, Nicholas C.P., Metzgeroth, Georgia, Reiter, Andreas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ferrata Storti Foundation
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5451335/ https://www.ncbi.nlm.nih.gov/pubmed/28255023 http://dx.doi.org/10.3324/haematol.2017.163964 |
Ejemplares similares
-
Functional imaging with dual-energy computed tomography for supplementary non-invasive assessment of mast cell burden in systemic mastocytosis
por: Riffel, Julia, et al.
Publicado: (2022) -
Response and resistance to cladribine in patients with advanced systemic mastocytosis: a registry-based analysis
por: Lübke, Johannes, et al.
Publicado: (2023) -
P1036: REAL-WORLD EFFICACY AND SAFETY OF MIDOSTAURIN-TREATMENT IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS
por: Lübke, Johannes, et al.
Publicado: (2023) -
Myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions: reevaluation of the defining characteristics in a registry-based cohort
por: Metzgeroth, Georgia, et al.
Publicado: (2023) -
MARS: Mutation-Adjusted Risk Score for Advanced Systemic Mastocytosis
por: Jawhar, Mohamad, et al.
Publicado: (2019)